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A ‘non-canonical’ DNA-binding element mediates the response
of the Fas-ligand promoter to c-Myc
Shailaja Kasibhatla*†, Helen M. Beere†, Thomas Brunner‡, Fernando Echeverri
and Douglas R. Green†
Cell number is regulated by maintaining a balance
between cell proliferation and cell death through
apoptosis. Key regulators of this balance include the
oncogene product c-Myc, which promotes either entry
into the cell cycle or apoptosis [1]. Although the
mechanism of c-Myc-induced apoptosis remains
unclear, it is susceptible to regulation by survival
factors [2,3] and can proceed through the interaction of
Fas ligand (FasL) with its receptor, Fas [4]. Activated
T lymphocytes are eliminated by an apoptotic process
known as activation-induced cell death (AICD), which
requires the transcriptional induction of FasL
expression [5–7] and sustained levels of c-Myc [8]. The
FasL promoter can be driven by c-Myc overexpression,
and functional inhibitors of Myc and its binding partner,
Max, inhibit the transcriptional activity of the FasL
promoter [9,10]. We identified a non-canonical binding
site (ATTCTCT) for c-Myc–Max heterodimers in the FasL
promoter, which, when mutated, abolished activity in
response to c-Myc. Exchange of the canonical c-Myc
responsive elements (CACGTG) in the ornithine
decarboxylase (ODC) promoter [11] with the non-
canonical sequence in the FasL promoter generated an
ODC–FasL promoter that was significantly more
responsive to c-Myc than the wild-type ODC promoter.
Our findings identify a precise physiological role for
c-Myc in the induction of apoptosis as a transcriptional
regulator of the FasL gene.
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Results and discussion
Although there are no canonical Myc-binding sites
(E boxes, CACGTG) in the region 1.2 kb upstream of
the FasL gene [12], examination of the FasL promoter
sequence revealed a site that has been described as a puta-
tive binding site for c-Myc in a number of genes, includ-
ing EF-II, Hsp70 and c-Myc itself (Figure 1a). To
examine whether this element was responsive to c-Myc
and could drive expression of the FasL promoter, we
coexpressed the 1.2 kb FasL promoter reporter construct
[12] with a c-Myc expression vector in Jurkat T cells. We
observed a significant activation of the FasL promoter in
response to elevated expression of c-Myc (Figure 1b). To
verify the specificity of this observation, we generated a
mutant FasL promoter construct containing base changes
within the putative Myc-binding region (ATTATCAC-
TAG, the substituted bases are italicized). This mutation
effectively eliminated the response of the FasL promoter
to c-Myc co-expression (Figure 1c) and to T-cell activa-
tion signals mimicked by phorbol 12-myristate 13-acetate
(PMA) plus ionomycin (data not shown).
Figure 1
Identification of a c-Myc-responsive element in the FasL promoter.
(a) Comparison of the consensus Myc-binding site (E box) with a
number of previously identified non-canonical Myc-responsive
elements [15,22–24], including the putative site in the FasL promoter.
(b) Overexpression of c-Myc enhances FasL promoter activity. Jurkat
cells were transiently co-transfected with the 1.2 kb FasL promoter
reporter construct (FasLPr) and increasing concentrations of c-Myc
expression vector or empty vector (pSP271) as indicated. Data are
expressed as mean relative luciferase units (± SD) and normalized to
β-galactosidase activity. (c) A mutation in the c-Myc-binding site
decreases c-Myc responsiveness of the FasL promoter. Jurkat cells
were transiently co-transfected with a mutant reporter construct and
increasing amounts of c-Myc expression vector as indicated. Data are
expressed as fold increase in luciferase activity. The results in (b,c) are
representative of at least three independent experiments, each carried
out in triplicate. The error bars indicate SD.
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EF-II CGTATTCTGA [23] 
HSP70 (HSP A)   GGGACTCTCCT [24]
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To determine whether the site we have identified in the
FasL promoter binds c-Myc, we generated a double-
stranded oligonucleotide probe containing this region of the
FasL promoter (Figure 2a). Proteins in nuclear extracts iso-
lated from the T-cell hybridoma line A1.1 bound this probe
in an electromobility shift assay (EMSA; Figure 2b). This
binding was effectively competed with an excess of unla-
belled oligonucleotide containing a canonical c-Myc-binding
sequence, CACGTG (Figure 2b, left). However, an oligonu-
cleotide containing a mutated FasL promoter sequence
(ATTATCA) was unable to compete for binding (Figure 2b,
right). This observation correlated with functional data
showing that this mutation, when introduced into the 1.2 kb
FasL promoter, abolished the responsiveness of the FasL
promoter construct to c-Myc (Figure 1c). 
Previous observations had indicated a potential role for
Max in the activity of c-Myc in regulating FasL transcrip-
tion and induction of AICD [9,10]. To examine more
directly the possibility that the site we have identified in
the FasL promoter binds to c-Myc and that its binding
partner, Max, may also be required, we used glutathione-S-
transferase (GST) fusions of Myc and Max proteins in the
EMSA. Myc and Max proteins bound as heterodimers to
both the non-canonical and the consensus site in the FasL
promoter (Figure 2c). However, c-Myc alone was only able
to recognise and bind the consensus sequence. Max alone
was unable to bind either the non-canonical or the consen-
sus Myc sites. These data indicate that the non-canonical
c-Myc-binding motif selectively binds Myc–Max het-
erodimers. Confirmation that recombinant GST–Myc and
Max (no GST tag) heterodimers formed a complex with
oligonucleotides containing canonical or non-canonical Myc
sites was shown by the detection of a supershifted complex
using an anti-GST antibody (Figure 2d).
We reasoned that if the sequence in the FasL promoter is
a bona fide Myc-responsive element, then it might substi-
tute for Myc-responsive elements in other promoters. The
ODC promoter responds to c-Myc and contains two
canonical Myc-binding sites [11]. We generated constructs
in which the Myc-binding sites in the ODC promoter
(denoted #1 and #2) were mutated and/or replaced with
the non-canonical c-Myc sequence from the FasL pro-
moter (Figure 3a). As shown in Figure 3b, the wild-type
ODC promoter (ODCwt) was induced by co-expression
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Figure 2
Recombinant Myc–Max heterodimers, but
not c-Myc alone, bind directly to the non-
canonical Myc-binding site in the FasL
promoter. (a) Sequence of the FasL
promoter region containing the putative c-
Myc responsive element (underlined) at
–120 bp upstream of the translation start
site. This sequence was used as a double-
stranded oligonucleotide for the EMSA
experiments. (b) Binding of nuclear
proteins to the non-canonical c-Myc-binding
site in the FasL promoter. Left, nuclear
extracts were incubated with the
radiolabeled oligonucleotide described in (a)
and binding was competed with increasing
amounts of the unlabelled consensus
oligonucleotide (CACGTG). Right, nuclear
extracts were incubated with radiolabeled
probe (ATTCTCT) described in (a) and
binding was competed with oligonucleotide
containing either a consensus Myc site or a
mutated Myc site in the FasL promoter.
(c) Binding of recombinant GST–Myc and
GST–Max to the Myc-binding site in the
FasL promoter. Left, the 32P-
labeled oligonucleotide from (a) was
incubated with GST–Myc and GST–Max
proteins as indicated and binding was
assessed by EMSA. Right, comparison of
binding of recombinant GST–Myc and
GST–Max to the consensus Myc-binding site.
Incubations are as follows: A, GST–Myc
(100 ng); B, GST–Myc (200 ng); C,
GST–Myc (500 ng); D, GST–Max
(100 ng); E, GST–Myc (200 ng) + GST–Max
(100 ng); F, GST–Myc (200 ng) +
GST–Max (200 ng); Probe (probe alone).
(d) Binding of recombinant GST–Myc and
Max (no GST tag) to the canonical and
non-canonical c-Myc-binding sites can be
supershifted using an anti-GST antibody.


























































































with c-Myc, and mutation of both of the Myc-binding
sites (ODC∆5A) decreased this responsiveness [11]. When
one (ODC∆5A–FasL#1) or both (ODC∆5A–FasL#1,#2)
the mutated sites were replaced with the non-canonical
Myc sequence, the Myc responsiveness of the ODC pro-
moter was restored to a level greater than that seen with
the wild-type promoter. We conclude that the non-
canonical Myc-binding site from the FasL promoter can
functionally replace canonical Myc-binding sites in an
established Myc-responsive promoter. 
We also performed the experiment by sequential
exchange of the two wild-type sequences in the ODC pro-
moter with the non-canonical binding sequence from the
FasL-promoter (ODCwt–FasL#1, ODCwt–FasL#2 and
ODCwt–FasL#1,#2). This generated a series of reporter
constructs that all exhibited an enhanced responsiveness
to c-Myc (Figure 3c) compared with ODCwt. These data
further implicate this region of the FasL promoter as a
Myc-responsive element.
We have previously shown that c-Myc is required for
AICD and FasL expression in T cells and T-cell hybrido-
mas [8–10]. Together with the data presented here, our
results implicate a non-canonical site in the FasL promoter
in binding the Myc–Max heterodimer, and which is neces-
sary but not sufficient for expression of the FasL gene.
Other transcription factors that are activated upon T-cell
receptor (TCR) ligation and that participate in FasL gene
expression include NF-AT, EGR-2 and NF-kB [13]. This
activation-induced FasL mRNA expression proceeds in
the presence of cycloheximide [14], which suggests that
the essential factors (including c-Myc) act directly to drive
the FasL promoter rather than through activation and
induced expression of other transcription factors. Together,
these transcription factors co-operate to optimally induce
activation of the FasL promoter, leading to gene expres-
sion. When FasL is expressed, it ligates its cell-surface
receptor Fas, which in turn engages the appropriate intra-
cellular machinery, culminating in activation of caspases
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Replacement of the consensus Myc-binding site(s) in the ODC
promoter with the non-canonical Myc-binding sites from the FasL
promoter sustains Myc responsiveness. (a) Constructs. One or both of
the consensus Myc-binding sites (#1 and #2) in the wild-type ODC
promoter (ODCwt) and the mutant Myc-binding sites in the ODC∆5A
promoter [11] were replaced with the non-canonical Myc-binding site
from the FasL promoter to generate a series of promoter reporter
constructs. (b) The non-canonical Myc-binding site from the FasL
promoter sustains Myc responsiveness in the ODC promoter.
Replacement of one (ODC∆5A–FasL#1) or both
(ODC∆5A–FasL#1,#2) the mutant c-Myc elements in the ODC∆5A
promoter with the non-canonical Myc sequence from the FasL
promoter. Jurkat T cells were transiently co-transfected with these
constructs in the presence or absence of a c-Myc expression vector
and luciferase activity assessed. (c) Replacement of one
(ODCwt–FasL#1 or ODCwt–FasL#2) or both (ODCwt–FasL#1, #2)
the consensus c-Myc elements in the ODCwt promoter with the non-
canonical Myc sequence from the FasL promoter. Jurkat cells were
transiently co-transfected with the ODCwt promoter chimeras in the
presence or absence of a c-Myc expression construct. Data in (b,c) are
expressed as relative luciferase units and normalised to
β-galactosidase activity. These results are representative of at least
three independent experiments, each carried out in triplicate. The error
bars indicate SD.
The site we have identified as a Myc-responsive site in
the FasL promoter is similar or identical to other sites that
have previously been suggested to be Myc responsive (see
Figure 1a). This site, however, is only remotely similar to
the well-established E box present in a number of Myc-
responsive promoters (including the ODC promoter) [11]
that were identified by direct binding of Myc to random-
ized oligonucleotides [15]. Why was the site that we have
identified not detected as Myc binding in such studies?
One possible answer is suggested by the observation
shown in Figure 2c in which oligonucleotides containing
this sequence failed to bind recombinant c-Myc (or did so
very poorly), but instead bound recombinant Myc–Max
heterodimer effectively. Notably, one of our earlier
studies described the requirement for Myc–Max het-
erodimers in AICD [10]. This difference in binding by
Myc versus Myc–Max (Figure 2c) may help account for
the difference in detection of sites such as we have identi-
fied versus the more conventional E-box-related sites. 
We recently reported that transforming growth factor-β
(TGF-β) suppresses the transcriptional activation of FasL
and AICD by the direct inhibition of c-Myc expression
[16]. Furthermore, interleukin-2 (IL-2) sensitizes T cells
to AICD and promotes elevated c-Myc expression [17],
making it tempting to speculate that c-Myc may con-
tribute to this sensitization process. These observations
support our belief that c-Myc plays a key role in regulating
FasL expression under physiologically relevant situations.
Why should FasL expression in lymphocytes be linked to
the expression and function of c-Myc? Only activated, pro-
liferating cells, and not  resting lymphocytes, express
c-Myc. As clonal expansion forms the basis of immune
responses, it is only the proliferating cells that may repre-
sent a threat to the body should they happen to be auto-
reactive (or even hyper-reactive, as these will also cause
extensive bystander damage). Re-stimulation of activated
cells therefore induces FasL, which in turn serves to check
cellular expansion by induction of apoptosis. Alternatively
(and non-exclusively), activated, proliferating lymphocytes
that take on effector functions do so, in part, through the
expression of FasL (except in this case they are resistant to
Fas-mediated death), which functions to kill Fas-expressing
cells with which they come in contact. By limiting this
expression to proliferating cells, it serves as a fail-safe mech-
anism to ensure that once the cells cease to express c-Myc
(for example, at the cessation of the response) expression of
this lethal molecule will also cease.
Supplementary material
Supplementary material including full Materials and methods is avail-
able at http://current-biology.com/supmat/supmatin.htm.
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